Wenbin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenbin Zhang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Fang-Zhou Jiao
Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China
3 shared publications - Hai-Yue Zhang
Renmin Hospital of Wuhan University
3 shared publications - Zuojiong Gong
Department of Infectious Diseases Renmin Hospital of Wuhan University Wuhan China
3 shared publications - Chunxia Shi
Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China
2 shared publications Dexin Xu
Department of Orthopedics, Jilin Province FAW General Hospital, Changchun, China
2 shared publications- Dexin Xu
Department of Orthopedics, Jilin Province FAW General Hospital, Changchun 130000, China
2 shared publications
Latest Publications
- 17 July 2026
- Published by Springer Nature in Pediatric Research
- p. 1-35
The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine
The future of pediatric gene therapy is being fundamentally reshaped by the convergence of CRISPR–Cas9 genome editing, artificial intelligence (AI), and personalized medicine, providing unprecedented opportunities for the treatment of rare and previously intractable genetic disorders in children. CRISPR–Cas9 enables precise and potentially curative correction of pathogenic mutations underlying conditions, such as sickle cell disease, cystic fibrosis, and Duchenne muscular dystrophy, with particularly notable progress in hematological disorders. AI-driven tools, like DeepCRISPR and CRISPR-GPT are emerging as valuable assets for streamlining experimental design, prioritizing candidate edits, and accelerating preclinical-to-clinical translation. In parallel, advances in delivery systems, including adeno-associated viral (AAV) vectors and non-viral platforms such as lipid nanoparticles (LNPs), are expanding the feasibility of both ex vivo and in vivo pediatric applications. The synergistic integration of CRISPR-Cas9, AI, and personalized medicine enables more precise, patient-specific therapeutic strategies that better account for the developmental, physiological, and genetic heterogeneity of pediatric populations. Addressing these challenges will require interdisciplinary collaboration across genome engineering, AI science, clinical pediatrics, bioethics, and regulatory policy. The establishment of standardized regulatory frameworks, accompanied by robust and transparent AI integration, will be essential to ensure safe, equitable, and scalable translation. Impact The future of pediatric gene therapy is being reshaped by the integration of CRISPR-Cas9, AI, and personalized medicine. We review recent clinical trials, including ex vivo CRISPR-Cas9 applications for hemoglobinopathies. This article emphasizes interdisciplinary collaboration to overcome these barriers. Pediatric gene therapy holds transformative potential to provide curative solutions for children.
- 17 July 2026
- Published by Springer Nature in Pediatric Research
- p. 1-35
The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine
The future of pediatric gene therapy is being fundamentally reshaped by the convergence of CRISPR–Cas9 genome editing, artificial intelligence (AI), and personalized medicine, providing unprecedented opportunities for the treatment of rare and previously intractable genetic disorders in children. CRISPR–Cas9 enables precise and potentially curative correction of pathogenic mutations underlying conditions, such as sickle cell disease, cystic fibrosis, and Duchenne muscular dystrophy, with particularly notable progress in hematological disorders. AI-driven tools, like DeepCRISPR and CRISPR-GPT are emerging as valuable assets for streamlining experimental design, prioritizing candidate edits, and accelerating preclinical-to-clinical translation. In parallel, advances in delivery systems, including adeno-associated viral (AAV) vectors and non-viral platforms such as lipid nanoparticles (LNPs), are expanding the feasibility of both ex vivo and in vivo pediatric applications. The synergistic integration of CRISPR-Cas9, AI, and personalized medicine enables more precise, patient-specific therapeutic strategies that better account for the developmental, physiological, and genetic heterogeneity of pediatric populations. Addressing these challenges will require interdisciplinary collaboration across genome engineering, AI science, clinical pediatrics, bioethics, and regulatory policy. The establishment of standardized regulatory frameworks, accompanied by robust and transparent AI integration, will be essential to ensure safe, equitable, and scalable translation. Impact The future of pediatric gene therapy is being reshaped by the integration of CRISPR-Cas9, AI, and personalized medicine. We review recent clinical trials, including ex vivo CRISPR-Cas9 applications for hemoglobinopathies. This article emphasizes interdisciplinary collaboration to overcome these barriers. Pediatric gene therapy holds transformative potential to provide curative solutions for children.
- Open Access
- 3 May 2025
- Published by Elsevier in SLAS Technology
- Vol. 32, 100301
Contrast-enhanced ultrasonography combined with microbubbles for uterine disorders: Current trends and future perspectives
- 3 May 2025
- Published by Elsevier in SLAS Technology
- Vol. 32, 100301
Open AccessContrast-enhanced ultrasonography combined with microbubbles for uterine disorders: Current trends and future perspectives
- 9 April 2025
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (3) , 484-497
Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward
Myocardial infarction (MI) is a global health concern that necessitates continued advancements in diagnostic and therapeutic modalities. Nanotechnology facilitates prompt diagnosis and personalized treatment. This manuscript explicitly reviews the application of innovative methodologies for identifying cardiac biomarkers to facilitate the early diagnosis of MI and its clinical management. Nanoscale agents such as nanoparticles and nanosensors have been employed for this purpose. Technological advancements in medical imaging are revolutionizing therapeutic approaches while reducing morbidity and mortality typically associated with cardiac tissue injury. Besides all, applications of nanotechnology in therapeutics have proven extremely effective. The development of nanoparticle-based customized drug delivery systems will contribute to more effective treatments, fewer side effects, and improved therapeutic outcomes. Biomaterials and nanoscale surgical technologies may benefit patients with MI by promoting tissue regeneration and repair. This manuscript also investigates the ethical and legal limitations that could prevent seamless incorporation of nanotechnology into clinical practice. Graphical Abstract
- 9 April 2025
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (3) , 484-497
Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward
Myocardial infarction (MI) is a global health concern that necessitates continued advancements in diagnostic and therapeutic modalities. Nanotechnology facilitates prompt diagnosis and personalized treatment. This manuscript explicitly reviews the application of innovative methodologies for identifying cardiac biomarkers to facilitate the early diagnosis of MI and its clinical management. Nanoscale agents such as nanoparticles and nanosensors have been employed for this purpose. Technological advancements in medical imaging are revolutionizing therapeutic approaches while reducing morbidity and mortality typically associated with cardiac tissue injury. Besides all, applications of nanotechnology in therapeutics have proven extremely effective. The development of nanoparticle-based customized drug delivery systems will contribute to more effective treatments, fewer side effects, and improved therapeutic outcomes. Biomaterials and nanoscale surgical technologies may benefit patients with MI by promoting tissue regeneration and repair. This manuscript also investigates the ethical and legal limitations that could prevent seamless incorporation of nanotechnology into clinical practice. Graphical Abstract
- Open Access
- 1 June 2024
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 9 (2) , 388-406
Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance
Long noncoding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that do not code for proteins but have been linked to cancer development and metastasis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) influences crucial cancer hallmarks through intricate molecular mechanisms, including proliferation, invasion, angiogenesis, apoptosis, and the epithelial-mesenchymal transition (EMT). The current article highlights the involvement of MALAT-1 in drug resistance, making it a potential target to overcome chemotherapy refractoriness. It discusses the impact of MALAT-1 on immunomodulatory molecules, such as major histocompatibility complex (MHC) proteins and PD-L1, leading to immune evasion and hindering anti-tumor immune responses. MALAT-1 also plays a significant role in cancer immunology by regulating diverse immune cell populations. In summary, MALAT-1 is a versatile cancer regulator, influencing tumorigenesis, chemoresistance, and immunotherapy responses. Understanding its precise molecular mechanisms is crucial for developing targeted therapies, and therapeutic strategies targeting MALAT-1 show promise for improving cancer treatment outcomes. However, further research is needed to fully uncover the role of MALAT-1 in cancer biology and translate these findings into clinical applications.
- 1 June 2024
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 9 (2) , 388-406
Open AccessLong noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance
Long noncoding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that do not code for proteins but have been linked to cancer development and metastasis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) influences crucial cancer hallmarks through intricate molecular mechanisms, including proliferation, invasion, angiogenesis, apoptosis, and the epithelial-mesenchymal transition (EMT). The current article highlights the involvement of MALAT-1 in drug resistance, making it a potential target to overcome chemotherapy refractoriness. It discusses the impact of MALAT-1 on immunomodulatory molecules, such as major histocompatibility complex (MHC) proteins and PD-L1, leading to immune evasion and hindering anti-tumor immune responses. MALAT-1 also plays a significant role in cancer immunology by regulating diverse immune cell populations. In summary, MALAT-1 is a versatile cancer regulator, influencing tumorigenesis, chemoresistance, and immunotherapy responses. Understanding its precise molecular mechanisms is crucial for developing targeted therapies, and therapeutic strategies targeting MALAT-1 show promise for improving cancer treatment outcomes. However, further research is needed to fully uncover the role of MALAT-1 in cancer biology and translate these findings into clinical applications.
- 30 November 2019
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 15 (2) , 196-208
AGK2 Alleviates Lipopolysaccharide Induced Neuroinflammation through Regulation of Mitogen-Activated Protein Kinase Phosphatase-1
Neuroinflammation is associated with the progression of multiple neurological diseases. Many studies show that SIRT2 involves in multiple inflammatory processes. While, the mechanisms remain unclear. The purpose of this study was to explore the effect of SIRT2 inhibitor AGK2 on inflammatory responses and MAPK signaling pathways in LPS activated microglia in vitro and in vivo. The effect of AGK2 on cell viability of BV2 microglial cells was detected by CCK-8 assay. The expression of inflammatory cytokine iNOS was analyzed by western blotting and immunofluorescence. The mRNA expressions of iNOS, TNF-α, and IL-1β were detected by real-time polymerase chain reaction (RT-PCR). The SIRT2, phospho-P38, P38, phospho-JNK, JNK, phospho-ERK, ERK, α-tubulin, and acetyl-α-tubulin were analyzed by western blotting respectively. The interaction between SIRT2 and MKP-1 was measured by Co-immunoprecipitation (Co-IP) assay. Double immunofluorescent staining was performed to detect the expressions of CD11b and iNOS or SIRT2 in brain tissues. We found that AGK2 could suppress LPS-induced inflammatory cytokines (iNOS, TNF-α, and IL-1β) expression levels in BV2 microglial cells. Moreover, it could effectively reduce the expression of SIRT2 and increase the acetylation of α-tubulin in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. In addition, our results showed that AGK2 could reduce the increase of phosphorylation p38, JNK, and ERK after LPS challenge. Co-IP results showed that there was no direct interaction between MKP-1 and SIRT2. However, AGK2 by inhibition of SIRT2 could increase the expression of MKP-1. Furthermore, AGK2 could inhibit the activation of BV2 microglia and expression of iNOS and SIRT2 in LPS treated mice brain tissue. Taken together, our results suggested that AGK2 might alleviate lipopolysaccharide induced neuroinflammation through regulation of mitogen-activated protein kinase phosphatase-1.
- 30 November 2019
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 15 (2) , 196-208
AGK2 Alleviates Lipopolysaccharide Induced Neuroinflammation through Regulation of Mitogen-Activated Protein Kinase Phosphatase-1
Neuroinflammation is associated with the progression of multiple neurological diseases. Many studies show that SIRT2 involves in multiple inflammatory processes. While, the mechanisms remain unclear. The purpose of this study was to explore the effect of SIRT2 inhibitor AGK2 on inflammatory responses and MAPK signaling pathways in LPS activated microglia in vitro and in vivo. The effect of AGK2 on cell viability of BV2 microglial cells was detected by CCK-8 assay. The expression of inflammatory cytokine iNOS was analyzed by western blotting and immunofluorescence. The mRNA expressions of iNOS, TNF-α, and IL-1β were detected by real-time polymerase chain reaction (RT-PCR). The SIRT2, phospho-P38, P38, phospho-JNK, JNK, phospho-ERK, ERK, α-tubulin, and acetyl-α-tubulin were analyzed by western blotting respectively. The interaction between SIRT2 and MKP-1 was measured by Co-immunoprecipitation (Co-IP) assay. Double immunofluorescent staining was performed to detect the expressions of CD11b and iNOS or SIRT2 in brain tissues. We found that AGK2 could suppress LPS-induced inflammatory cytokines (iNOS, TNF-α, and IL-1β) expression levels in BV2 microglial cells. Moreover, it could effectively reduce the expression of SIRT2 and increase the acetylation of α-tubulin in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. In addition, our results showed that AGK2 could reduce the increase of phosphorylation p38, JNK, and ERK after LPS challenge. Co-IP results showed that there was no direct interaction between MKP-1 and SIRT2. However, AGK2 by inhibition of SIRT2 could increase the expression of MKP-1. Furthermore, AGK2 could inhibit the activation of BV2 microglia and expression of iNOS and SIRT2 in LPS treated mice brain tissue. Taken together, our results suggested that AGK2 might alleviate lipopolysaccharide induced neuroinflammation through regulation of mitogen-activated protein kinase phosphatase-1.
- 1 August 2019
- Published by Elsevier in Life Sciences
- Vol. 230, 68-75
Protective role of AGK2 on thioacetamide-induced acute liver failure in mice
- 1 August 2019
- Published by Elsevier in Life Sciences
- Vol. 230, 68-75
Protective role of AGK2 on thioacetamide-induced acute liver failure in mice
- 19 April 2018
- Published by Springer Nature in Neurochemical Research
- Vol. 43 (6) , 1161-1170
Histone Deacetylase 2 Inhibitor CAY10683 Alleviates Lipopolysaccharide Induced Neuroinflammation Through Attenuating TLR4/NF-κB Signaling Pathway
Neuroinflammation involves in the progression of many central nervous system diseases. Several studies have shown that histone deacetylase (HDAC) inhibitors modulated inflammatory responses in lipopolysaccharide (LPS) stimulated microglia. While, the mechanism is still unclear. The aim of present study was to investigate the effect of HDAC2 inhibitor CAY10683 on inflammatory responses and TLR4/NF-κB signaling pathways in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. The effect of CAY10683 on cell viability of BV2 microglial cells was detected by CCK-8 assay. The expressions of inflammatory cytokines were analyzed by western blotting and RT-PCR respectively. The TLR4 protein expression was measured by western blotting, immunofluorescence, immunohistochemistry respectively. The protein expressions of MYD88, phospho-NF-κB p65, NF-κB-p65, acetyl-H3 (AH3), H3, and HDAC2 were analyzed by western blotting. We found that CAY10683 could inhibit expression levels of inflammatory cytokine TNF-α and IL-1β in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. It could induce TLR4, MYD88, phospho-NF-κB p65, and HDAC2 expressions. Moreover, CAY10683 increased the acetylation of histones H3 in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. Taken together, our findings suggested that HDAC2 inhibitor CAY10683 could suppress neuroinflammatory responses and TLR4/NF-κB signaling pathways by acetylation after LPS stimulation.
- 19 April 2018
- Published by Springer Nature in Neurochemical Research
- Vol. 43 (6) , 1161-1170
Histone Deacetylase 2 Inhibitor CAY10683 Alleviates Lipopolysaccharide Induced Neuroinflammation Through Attenuating TLR4/NF-κB Signaling Pathway
Neuroinflammation involves in the progression of many central nervous system diseases. Several studies have shown that histone deacetylase (HDAC) inhibitors modulated inflammatory responses in lipopolysaccharide (LPS) stimulated microglia. While, the mechanism is still unclear. The aim of present study was to investigate the effect of HDAC2 inhibitor CAY10683 on inflammatory responses and TLR4/NF-κB signaling pathways in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. The effect of CAY10683 on cell viability of BV2 microglial cells was detected by CCK-8 assay. The expressions of inflammatory cytokines were analyzed by western blotting and RT-PCR respectively. The TLR4 protein expression was measured by western blotting, immunofluorescence, immunohistochemistry respectively. The protein expressions of MYD88, phospho-NF-κB p65, NF-κB-p65, acetyl-H3 (AH3), H3, and HDAC2 were analyzed by western blotting. We found that CAY10683 could inhibit expression levels of inflammatory cytokine TNF-α and IL-1β in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. It could induce TLR4, MYD88, phospho-NF-κB p65, and HDAC2 expressions. Moreover, CAY10683 increased the acetylation of histones H3 in LPS activated BV2 microglial cells and LPS induced mice neuroinflammation. Taken together, our findings suggested that HDAC2 inhibitor CAY10683 could suppress neuroinflammatory responses and TLR4/NF-κB signaling pathways by acetylation after LPS stimulation.